Compound Screening TRIZ Cases

Known antiviral peptides can have limited membrane activity; Swiss-Prot-derived amphipathic α-helices disrupt enveloped-virus lipid membranes.

Split CAT enables chloramphenicol selection in rich media, shortening growth time for rapid protein-interaction screening.

Conserved US28 epitopes enable binding molecules to recognize diverse HCMV strains while limiting off-target activity on healthy cells.

Small i-bodies block RANK-L/RANK signaling to inhibit osteoclast differentiation, addressing the tissue-penetration limits of full antibodies.

Reconstituted membrane assays and engineered G proteins address noisy, low-fidelity cell screening while isolating ligands with defined pharmacology.

Computationally identified SARS-CoV-2 MHC-I peptides focus immunogenic compositions on cytotoxic T-cell responses for vaccine development.

Cellular screening identifies lipoic acid and lipoamide as lower-toxicity modulators that reduce stress granule formation in ALS and related diseases.

Single-domain binders distinguish plasmin-cleaved VWF from intact and ADAMTS13-cleaved forms, supporting accurate detection.

Tumor-proximal lymphatic fluid biomarkers add local diagnostic information for candidate therapy selection beyond blood-based testing.

Fluorophore-bound peptides and detergent micelles convert acylation into a fluorescence-polarization signal for rapid inhibitor screening.

Fresh NSCLC tissue is cultured ex vivo to test ICI response while Hom-1 activation in TAMs promotes tumor-specific CD8+ T-cell activity.

Limited adult neurogenesis is addressed by Plagl2 activation and Dyrk1a suppression to stimulate endogenous neural stem cells.

Arginine-rich transcription-factor regions bind regulatory RNA, while targeted oligonucleotides modulate gene expression and TF occupancy.

Existing angiogenesis treatments may not suppress abnormal vessel growth; one peptide blocks both VEGF and PDGF receptors.

Long-term treatment of intact tumor tissue preserves immune and stromal interactions for more predictive candidate-molecule evaluation.

Engineered reporter T cells measure LAG-3 agonist activity without primary-cell variability or natural-ligand interference.

Monitoring Syt7 expression links bipolar symptoms to a biomarker for diagnosis and targeted molecular treatment.

Merged droplets combine plasmid expression with GPCR sensing to address slow loading and limited interaction monitoring in peptide screens.

Combining RUNX3 with CDK4 or mTOR inhibitors maintains RUNX3-BRD2 binding for up to 8 hours and increases apoptosis in deficient cancer cells.

FRET probes reveal how TIPS factors alter antibody structure, enabling inhibitor screening to restore therapeutic activity.

Dual-labeled Fab and Fc fluorophores use FRET to reveal TIPS-driven antibody changes and screen inhibitors that preserve immune engagement.

Using physiologic albumin concentrations in hepatocyte cultures preserves drug binding behavior, improving prediction of in vivo disposition and effects.

Conventional assays struggle with protein interactions across different cells; proximity-induced cleavage releases tags for sensitive quantitation.

Clostridium spores and chloroform-treated fractions induce regulatory T cells, helping suppress effector T-cell proliferation and immune functions.

Poor pharmacokinetics can make mitofusin activators undruggable; this case uses allosteric molecules to restore mitochondrial fusion and transport.

Saturation mutagenesis of ERBB2 residues 679–992 enables high-throughput phosphorylation screening to identify cancer-relevant variants.

AxCBM1 and AxCBM2 biomarkers bind CB1 and CB2 in human cells for real-time receptor activity testing without animal models.

This case uses patch clamp and pH-sensitive fluorescence to characterize otopetrin proton translocation and screen modulators.

Split reporter fragments reveal GA receptor binding and conformational change while reducing plant material needs.

Engineered chimeric and humanized antibodies bind PAUF with affinity, inhibiting cancer-cell proliferation, migration, invasion, and growth.

This case uses T2R receptor assays to identify bitter blockers for simpler, more cost-effective oral API formulations.

Engineered A2M bait regions enhance protease inhibition for targeted control of FAC formation, inflammation, and tissue degeneration.

This case uses targeted COX2 binding to support rapid detection of overexpression despite blood-brain barrier permeability limits.

The case replaces subjective odor testing with receptor-based screening to identify substances that suppress specific offensive odors.

This case uses anti-CD47 antibodies to block CD47-SIRPα interaction on leukemia cells and mimetics to protect hematopoietic stem cells.

This case uses SYT11 inhibitors to curb cancer invasion and metastasis, while SYT11 expression supports earlier gastric cancer detection.

GRIP Display uses boxB RNA hairpins and lambda peptides to stabilize protein-mRNA linkage for large in vitro libraries.

This case uses RNA interference, CRISPR, or other GLIS2-downregulating agents to reduce ADPKD cyst progression beyond tolvaptan.

Measure glycosphingolipid recovery after CBE challenge to detect aberrant processing and assess disease severity or treatment response.

This case examines vIRF3 aa 250-280 peptide inhibition of PKM2 to suppress tumor growth, migration, and invasion.

A modular assay uses tagged PGRN, host cells, and fluorescent imaging to identify transmembrane and intracellular binding partners.

This screening approach tracks ERK, keratin 8, E-cadherin, and vimentin to identify agents that may limit EMT progression.

Anti-CD47 antibodies restore phagocytosis for tumor and leukemia cell clearance.

This case uses spore-forming Clostridium bacteria to accumulate Treg cells and suppress immune responses despite unclear mechanisms.

This case uses 36 human microRNAs, including AAV delivery, to stimulate adult cardiomyocyte proliferation after cardiac injury.

This case shows how selective Y705 phosphorylation inhibition can induce TNBC apoptosis while minimizing off-target effects.

Selected additives suppress nitrosation without destabilizing active ingredients.

Luminon probes use molecular recognition and FRET to appraise proteoform quality beyond conventional LC-MS/MS.

Targeted TSLP, TSLPR, and IL7RA gene humanization improves rodent models for studying allergic disease and cancer pathogenesis.

This case uses FRET and kinase assays to screen Plk1 activators that trigger chromosome abnormalities and cancer cell death.